A legal challenge aimed at blocking a clinical trial into puberty blockers in England has been thrown out by a High Court judge, clearing the way for the research to go ahead south of the border. But what does this mean for Scotland, where the debate around gender medicine for young people has been running hot for some time now?
The clinical trial, which will examine the benefits and risks of puberty blockers in teenagers, was challenged in court by campaigners who wanted to halt the research before it could begin. The judge dismissed that challenge, meaning the trial will now proceed in England under strict clinical conditions.
Scotland has already taken its own path on this issue. The Scottish Government moved to restrict the prescribing of puberty blockers to under-18s outside of clinical trials following the publication of the landmark Cass Review last year. That independent review, led by Dr Hilary Cass, found there was not enough reliable evidence to support the routine use of puberty blockers in young people experiencing gender distress, and called for a much more cautious approach.
In response, NHS Scotland paused the prescribing of these drugs for new patients under 18, bringing it broadly into line with the position taken in England and Wales. The Sandyford clinic in Glasgow, which had been one of the main providers of gender identity services for young people in Scotland, has been operating under that more restricted framework since the review landed.
The Scottish Government has faced pressure from both sides of the argument. Trans rights campaigners and some medical professionals have argued that blocking access to puberty blockers causes serious harm to young people with gender dysphoria, pointing to studies suggesting the drugs can reduce distress and improve mental health outcomes. On the other side, a growing number of clinicians, researchers and parents have raised concerns about the long-term physical effects of the treatment and whether young teenagers are able to give fully informed consent.
The Cass Review essentially handed Scottish ministers political cover to tighten restrictions, but it has not ended the debate by any stretch. Several legal cases and ongoing disputes about NHS waiting times for gender services continue to rumble on across Scotland.
The English clinical trial that has now been given the green light is seen by some as a potential way to finally generate the kind of robust, long-term data that has been missing from this area of medicine. If the trial produces solid evidence one way or the other, it could eventually influence how Scotland approaches the issue going forward, though any such impact would likely be years away.
For now, young people in Scotland seeking gender-related medical treatment face a system that is significantly more cautious than it was just a few years ago. Waiting lists for the Sandyford and other services remain long, and many families have spoken publicly about the frustration of navigating a system that feels, to them, like it has been shut down rather than reformed.
The Scottish Government has said it remains committed to providing care and support for young people with gender dysphoria, but has stressed that any treatment must be evidence-based and delivered safely. That position is unlikely to shift in the near term, regardless of what happens with the English trial.
What the court ruling in England does confirm is that the clinical and legal arguments around puberty blockers are far from over. The trial will now gather evidence that researchers, clinicians and policymakers across the UK, including in Scotland, will be watching closely.
Scotland’s always done its own thing and honestly fair enough. The whole puberty blockers debate is so complicated and I don’t think either side is making it easy for families who are just trying to figure out what’s best for their kids.